Intra- and inter-clade cross-reactivity by HIV-1 gag specific T-cells reveals exclusive and commonly targeted regions: Implications for current vaccine trials

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Zembe, Lycias ^a   Burgers, Wendy A ^a   Jaspan, Heather B ^a,b   Bekker, Linda Gail ^b   Bredell, Helba ^a   Stevens, Gwynneth ^c   Gilmour, Jill ^c   Cox, Josephine H ^c   Fast, Patricia ^c   Hayes, Peter ^c   Vardas, Eftyhia ^d   Williamson, Carolyn ^a   Gray, Clive M ^a,e  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b University of Town   (South Africa)

^c INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HLA ANTIGEN CLASS 1; PEPTIDE;

ADULT; ARTICLE; CHINA; CLADISTICS; CONSENSUS; CONTROLLED STUDY; CROSS REACTION; ENTROPY; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PROTEIN PROCESSING; SOUTH AFRICA; STRUCTURAL GENE; T LYMPHOCYTE; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; CHEMISTRY; CLASSIFICATION; CLINICAL TRIAL (TOPIC); GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MIDDLE AGED; MOLECULAR GENETICS; PHYSIOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; AIDS VACCINES; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; CLINICAL TRIALS AS TOPIC; CROSS REACTIONS; EPITOPES; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV-1; HUMANS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN PROCESSING, POST-TRANSLATIONAL; T-LYMPHOCYTES; YOUNG ADULT;

EID: 80053995831     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026096     Document Type: Article

References (63)

1. Choisy M, Woelk CH, Guegan JF, Robertson DL, (2004) Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypes. J Virol 78 (4): 1962-1970.
2. Wolinsky SM, Korber BT, Neumann AU, Daniels M, Kunstman KJ, et al. (1996) Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 272 (5261): 537-542.
3. Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, et al. (2006) Fitness cost of escape mutations in p24 gag in association with control of human immunodeficiency virus type 1. J Virol 80 (7): 3617-3623.
4. Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra F, et al. (2009) HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. J Virol 83 (6): 2743-2755.
5. Frahm N, Kiepiela P, Adams S, Linde CH, Hewitt HS, et al. (2006) Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 7 (2): 173-178.
6. Edwards BH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, et al. (2002) Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 76 (5): 2298-2305.
7. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, et al. (2007) CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13 (1): 46-53.
8. Masemola A, Mashishi T, Khoury G, Mohube P, Mokgotho P, et al. (2004) Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: Correlation with viral load. J Virol 78 (7): 3233-3243.
9. Zuniga R, Lucchetti A, Galvan P, Sanchez S, Sanchez C, et al. (2006) Relative dominance of gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol 80 (6): 3122-3125.
10. Geldmacher C, Currier JR, Herrmann E, Haule A, Kuta E, et al. (2007) CD8 T-cell recognition of multiple epitopes within specific gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients. J Virol 81 (5): 2440-2448.
11. Geels MJ, Dubey SA, Anderson K, Baan E, Bakker M, et al. (2005) Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): Importance of HLA anchor residue conservation. J Virol 79 (17): 11247-11258.
12. Gupta SB, Mast CT, Wolfe ND, Novitsky V, Dubey SA, et al. (2006) Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from botswana and cameroon. J Acquir Immune Defic Syndr 42 (2): 135-139.
13. Gudmundsdotter L, Bernasconi D, Hejdeman B, Sandstrom E, Alaeus A, et al. (2008) Cross-clade immune responses to gag p24 in patients infected with different HIV-1 subtypes and correlation with HLA class I and II alleles. Vaccine 26 (40): 5182-5187.
14. Geldmacher C, Currier JR, Gerhardt M, Haule A, Maboko L, et al. (2007) In a mixed subtype epidemic, the HIV-1 gag-specific T-cell response is biased towards the infecting subtype. AIDS 21 (2): 135-143.
15. McKinnon LR, Ball TB, Kimani J, Wachihi C, Matu L, et al. (2005) Cross-clade CD8(+) T-cell responses with a preference for the predominant circulating clade. J Acquir Immune Defic Syndr 40 (3): 245-249.
16. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, et al. (2011) Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in south africa: A double-blind, randomised, placebo-controlled test-of-concept phase 2 b study. Lancet Infect Dis 11 (7): 507-15.
17. Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, et al. (2007) Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity. Vaccine 25 (11): 2120-2127.
18. Vardas E, Kaleebu P, Bekker LG, Hoosen A, Chomba E, et al. (2010) A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus. AIDS Res Hum Retroviruses 26 (8): 933-942.
19. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in thailand. N Engl J Med 361 (23): 2209-2220.
20. Kresge KJ, (2009) South african AIDS vaccine initiative launches phase I trial. IAVI Rep 13 (4): 19.
21. Vasan S, Schlesinger SJ, Chen Z, Hurley A, Lombardo A, et al. (2010) Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia ankara-HIV-1 B'/C candidate vaccine. PLoS One 5 (1): e8816.
22. Vasan S, Schlesinger SJ, Huang Y, Hurley A, Lombardo A, et al. (2010) Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One 5 (1): e8617.
23. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, et al. (2001) Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 58: 19-42.
24. Currier JR, Dowling WE, Wasunna KM, Alam U, Mason CJ, et al. (2003) Detection of high frequencies of HIV-1 cross-subtype reactive CD8 T lymphocytes in the peripheral blood of HIV-1-infected kenyans. AIDS 17 (15): 2149-2157.
25. Buseyne F, Chaix ML, Fleury B, Manigart O, Burgard M, et al. (1998) Cross-clade-specific cytotoxic T lymphocytes in HIV-1-infected children. Virology 250 (2): 316-324.
26. Ferrari G, Humphrey W, McElrath MJ, Excler JL, Duliege AM, et al. (1997) Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A 94 (4): 1396-1401.
27. Cao H, Mani I, Vincent R, Mugerwa R, Mugyenyi P, et al. (2000) Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: Relevance to HIV-1 vaccine trials in uganda. J Infect Dis 182 (5): 1350-1356.
28. Aidoo M, Sawadogo S, Bile EC, Yang C, Nkengasong JN, et al. (2008) Viral, HLA and T cell elements in cross-reactive immune responses to HIV-1 subtype A, CRF01_AE and CRF02_AG vaccine sequence in ivorian blood donors. Vaccine 26 (37): 4830-4839.
29. Yu XG, Lichterfeld M, Perkins B, Kalife E, Mui S, et al. (2005) High degree of inter-clade cross-reactivity of HIV-1-specific T cell responses at the single peptide level. AIDS 19 (14): 1449-1456.
30. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, et al. (2003) Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 77 (3): 2081-2092.
31. Bansal A, Sabbaj S, Edwards BH, Ritter D, Perkins C, et al. (2003) T cell responses in HIV type 1-infected adolescent minorities share similar epitope specificities with whites despite significant differences in HLA class I alleles. AIDS Res Hum Retroviruses 19 (11): 1017-1026.
32. Williamson C, Morris L, Maughan MF, Ping LH, Dryga SA, et al. (2003) Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses 19 (2): 133-144.
33. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372 (9653): 1881-1893.
34. Hemelaar J, Gouws E, Ghys PD, Osmanov S, WHO-UNAIDS Network for HIV Isolation, Characterisation, (2011) Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 25 (5): 679-689.
35. Frahm N, Kaufmann DE, Yusim K, Muldoon M, Kesmir C, et al. (2007) Increased sequence diversity coverage improves detection of HIV-specific T cell responses. J Immunol 179 (10): 6638-6650.
36. Rolland M, Frahm N, Nickle DC, Jojic N, Deng W, et al. (2011) Increased breadth and depth of cytotoxic T lymphocytes responses against HIV-1-B nef by inclusion of epitope variant sequences. PLoS One 6 (3): e17969.
37. Malhotra U, Nolin J, Mullins JI, McElrath MJ, (2007) Comprehensive epitope analysis of cross-clade gag-specific T-cell responses in individuals with early HIV-1 infection in the US epidemic. Vaccine 25 (2): 381-390.
38. Altfeld M, Addo MM, Shankarappa R, Lee PK, Allen TM, et al. (2003) Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol 77 (13): 7330-7340.
39. Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, et al. (2010) Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 16 (3): 319-323.
40. Kong WP, Wu L, Wallstrom TC, Fischer W, Yang ZY, et al. (2009) Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol 83 (5): 2201-2215.
41. Santra S, Liao HX, Zhang R, Muldoon M, Watson S, et al. (2010) Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 16 (3): 324-328.
42. Allen TM, Altfeld M, Yu XG, O'Sullivan KM, Lichterfeld M, et al. (2004) Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol 78 (13): 7069-7078.
43. Carlson JM, Brumme ZL, (2008) HIV evolution in response to HLA-restricted CTL selection pressures: A population-based perspective. Microbes Infect 10 (5): 455-461.
44. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, et al. (2009) Adaptation of HIV-1 to human leukocyte antigen class I. 458 (7238) Nature: 641-645.
45. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, et al. (2004) Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432 (7018): 769-775.
46. Dong T, Zhang Y, Xu KY, Yan H, James I, et al. (2011) Extensive HLA-driven viral diversity following a narrow-source HIV-1 outbreak in rural china. Blood 118 (1): 98-106.
47. Rolland M, Tovanabutra S, deCamp AC, Frahm N, Gilbert PB, et al. (2011) Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 17 (3): 366-371.
48. John M, Heckerman D, James I, Park LP, Carlson JM, et al. (2010) Adaptive interactions between HLA and HIV-1: Highly divergent selection imposed by HLA class I molecules with common supertype motifs. J Immunol 184 (8): 4368-4377.
49. Moore CB, John M, James IR, Christiansen FT, Witt CS, et al. (2002) Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296 (5572): 1439-1443.
50. Woo J, Robertson DL, Lovell SC, (2010) Constraints on HIV-1 diversity from protein structure. 84 (24) J Virol: 12995-3003.
51. McKinney DM, Skvoretz R, Livingston BD, Wilson CC, Anders M, et al. (2004) Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL. J Immunol 173 (3): 1941-1950.
52. Rolland M, Nickle DC, Mullins JI, (2007) HIV-1 group M conserved elements vaccine. PLoS Pathog 3 (11): e157.
53. Rosario M, Bridgeman A, Quakkelaar ED, Quigley MF, Hill BJ, et al. (2010) Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol 40 (7): 1973-1984.
54. Letourneau S, Im EJ, Mashishi T, Brereton C, Bridgeman A, et al. (2007) Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2 (10): e984.
55. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, et al. (2007) Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 13 (1): 100-106.
56. Li F, Finnefrock AC, Dubey SA, Korber BT, Szinger J, et al. (2011) Mapping HIV-1 vaccine induced T-cell responses: Bias towards less-conserved regions and potential impact on vaccine efficacy in the step study. PLoS One 6 (6): e20479.
57. Bredell H, Martin DP, Van Harmelen J, Varsani A, Sheppard HW, et al. (2007) HIV type 1 subtype C gag and nef diversity in southern africa. AIDS Res Hum Retroviruses 23 (3): 477-481.
58. Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, et al. (2008) NetMHC-3.0: Accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. 36 (Web Server issue) Nucleic Acids Res: W509-12.
59. Lundegaard C, Lund O, Nielsen M, (2008) Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics 24 (11): 1397-1398.
60. Peters B, Bulik S, Tampe R, Van Endert PM, Holzhutter HG, (2003) Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J Immunol 171 (4): 1741-1749.
61. Peters B, Tong W, Sidney J, Sette A, Weng Z, (2003) Examining the independent binding assumption for binding of peptide epitopes to MHC-I molecules. Bioinformatics 19 (14): 1765-1772.
62. Tenzer S, Peters B, Bulik S, Schoor O, Lemmel C, et al. (2005) Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol Life Sci 62 (9): 1025-1037.
63. Horig H, Young AC, Papadopoulos NJ, DiLorenzo TP, Nathenson SG, (1999) Binding of longer peptides to the H-2 Kb heterodimer is restricted to peptides extended at their C terminus: Refinement of the inherent MHC class I peptide binding criteria. J Immunol 163 (8): 4434-4441.